Fibroblast growth factor receptor 2 gene (FGFR2) rs2981582T/C polymorphism and susceptibility to breast cancer in Saudi women

AlRaddadi, Rawya Ibrahim Rabeh; Alamri, Razan Jamaan Nafaa; Shebli, Weam Talal Yehya; Fallatah, Emad Ibrahim Yagoub; Alhujaily, Ahmed Safar; Mohamed, Hiba S.; Alotibi, Mohammad Kdaimes H.

doi:10.1016/j.sjbs.2021.07.005

Cited by 2 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…224 Moreover, activating mutations in FGFR2 also induce Golgi fragmentation, loss of polarity, and directional migration. 225 In addition, gene polymorphisms of FGFR2, including rs2981582, [226][227][228][229] rs1219648, 230,231 rs35054928, and rs45631563, 232 have been found to be associated with susceptibility to breast cancer. In breast cancer, FGFR2 activates multiple pathways.…”

Section: Role and Signal Network Of Fgfr2 In Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

FGFR families: biological functions and therapeutic interventions in tumors

Liu,

Huang,

Yan

et al. 2023

MedComm

View full text Add to dashboard Cite

There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and autophosphorylates, thereby activating several key downstream pathways that play an important role in normal physiology, such as the Ras/Raf/mitogen‐activated protein kinase kinase/extracellular signal‐regulated kinase, phosphoinositide 3‐kinase (PI3K)/AKT, phospholipase C gamma/diacylglycerol/protein kinase c, and signal transducer and activator of transcription pathways. Furthermore, as an oncogene, FGFR genetic alterations were found in 7.1% of tumors, and these alterations include gene amplification, gene mutations, gene fusions or rearrangements. Therefore, FGFR amplification, mutations, rearrangements, or fusions are considered as potential biomarkers of FGFR therapeutic response for tyrosine kinase inhibitors (TKIs). However, it is worth noting that with increased use, resistance to TKIs inevitably develops, such as the well‐known gatekeeper mutations. Thus, overcoming the development of drug resistance becomes a serious problem. This review mainly outlines the FGFR family functions, related pathways, and therapeutic agents in tumors with the aim of obtaining better outcomes for cancer patients with FGFR changes. The information provided in this review may provide additional therapeutic ideas for tumor patients with FGFR abnormalities.

show abstract

Section: Role and Signal Network Of Fgfr2 In Tumorsmentioning

confidence: 99%

“…In addition, gene polymorphisms of FGFR2, including rs2981582, 226 , 227 , 228 , 229 rs1219648, 230 , 231 rs35054928, and rs45631563, 232 have been found to be associated with susceptibility to breast cancer. In breast cancer, FGFR2 activates multiple pathways.…”

Section: Fgfr Is Involved In Human Tumorsmentioning

confidence: 99%

FGFR families: biological functions and therapeutic interventions in tumors

Liu,

Huang,

Yan

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…The FGFR2 SNP that is most commonly associated with breast cancer in women of European ancestry, rs2981582 ( 17 ), was recently also associated with an increased risk of breast cancer in Saudi Arabian women ( 25 ), and with luminal A breast cancer in Han Chinese women ( 26 ) and Korean women ( 27 ). The expression of the minor allele was associated with early-onset breast cancer in Indonesian women ( 28 ).…”

Section: Introductionmentioning

confidence: 99%

FGFR2 genetic variants in women with breast cancer

Dix‑Peek,

Dickens,

Augustine

et al. 2023

Mol Med Rep

View full text Add to dashboard Cite

Black African populations are more genetically diverse than others, but genetic variants have been studied primarily in European populations. The present study examined the association of four single nucleotide polymorphisms (SNPs) of the fibroblast growth factor receptor 2, associated with breast cancer in non-African populations, with breast cancer in Black, southern African women. Genomic DNA was extracted from whole blood samples of 1,001 patients with breast cancer and 1,006 controls (without breast cancer), and the rs2981582, rs35054928, rs2981578, and rs11200014 polymorphisms were analyzed using allele-specific Kompetitive allele-specific PCR™, and the χ 2 or Fisher's exact tests were used to compare the genotype frequencies. There was no association between those SNPs and breast cancer in the studied cohort, although an association was identified between the C/C homozygote genotype for rs2981578 and invasive lobular carcinoma. These results show that genetic biomarkers of breast cancer risk in European populations are not necessarily associated with risk in sub-Saharan African populations. African populations are more heterogenous than other populations, and the information from this population can help focus genetic risks of cancer in this understudied population.

show abstract

Fibroblast growth factor receptor 2 gene (FGFR2) rs2981582T/C polymorphism and susceptibility to breast cancer in Saudi women

Cited by 2 publications

References 33 publications

FGFR families: biological functions and therapeutic interventions in tumors

FGFR families: biological functions and therapeutic interventions in tumors

FGFR2 genetic variants in women with breast cancer

Contact Info

Product

Resources

About